Farnesol, a potential efflux pump inhibitor in mycobacterium smegmatis

Molecules

Volumn 15, Issue 11, 2010, Pages 7750-7762

  Jin, Jing ^a   Zhang, Ji Yu ^b   Guo, Na ^a   Sheng, Hui ^c   Li, Lei ^a   Liang, Jun Chao ^a   Wang, Xue Lin ^a   Li, Yang ^a   Liu, Ming Yuan ^a   Wu, Xiu Ping ^a   Yu, Lu ^a  

^a JILIN UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Efflux pump; Farnesol; Inhibitor; Mycobacterium smegmatis

Indexed keywords

BACTERIAL PROTEIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CARRIER PROTEIN; CHLORPROMAZINE; FARNESOL; MESOXALONITRILE; NITRILE; RESERPINE; TUBERCULOSTATIC AGENT; VERAPAMIL;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM SMEGMATIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; CHLORPROMAZINE; FARNESOL; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; NITRILES; RESERPINE; VERAPAMIL;

EID: 78649470584     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15117750     Document Type: Article

References (38)

1. Han, X.Y.; Dé, I.; Jacobson, K.L. Rapidly growing mycobacteria: Clinical and microbiologic studies of 115 cases. Am. J. Clin. Pathol. 2007, 128, 612-621.
2. World Health Organization. Global Tuberculosis Control: Epidemiology, strategy, financing; WHO/HTM/TB: Geneva, Switzerland, 2009; p. 411.
3. Bloom, B.R.; Murray, C.J. Tuberculosis: Commentary on a reemergent killer. Science 1992, 257, 1055-1064.
4. German, N.; Kaatz, G.W.; Kerns, R.J. Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps. Bioorg. Med. Chem. Lett. 2008, 18, 1368-1373.
5. De Rossi, E.; Aínsa, J.A.; Riccardi, G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 2006, 30, 36-52.
6. Gupta, A.K.; Chauhan, D.S.; Srivastava, K.; Das, R.; Batra, S.; Mittal, M.;, Goswami, P.; Singhal, N.; Sharma, V.D.; Venkatesan, K.; Hasnain, S.E.; Katoch, V.M. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. Commun. Dis. 2006, 38, 246-254.
7. Marquez, B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005, 87, 1137-1147.
8. Lechner, D.; Gibbons, S.; Bucar, F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J. Antimicrob. Chemother. 2008, 62, 345-348.
9. Rodrigues, L.; Wagner, D.; Viveiros, M.; Sampaio, D.; Couto, I.; Vavra, M.; Kern, W.V.; Amaral, L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother. 2008, 61, 1076-1082.
10. Gibbons, S.; Oluwatuyi, O.; Kaatz, G.W. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J. Antimicrob. Chemother. 2003, 51, 13-17.
11. Piddock, L.J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacterial. Clin. Microbiol. Rev. 2006, 19, 382-402.
12. Kuroda, M.; Nagasaki, S.; Ohta, T. Sesquiterpene farnesol inhibits recycling of the C55 lipid carrier of the murein monomer precursor contributing to increased susceptibility to beta-lactams in methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2007, 59, 425-432.
13. Brehm-Stecher, B.F.; Johnson, E.A. Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob. Agents Chemother. 2003, 47, 3357-3360.
14. Jabra-Rizk, M.A.; Meiller, T.F.; James, C.E. Shirtliff, M.E. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob. Agents Chemother. 2006, 50, 1463-1469.
15. Inoue, Y.; Shiraishi, A.; Hada, T.; Hirose, K.; Hamashima, H.; Shimada, J. The antibacterial effects of terpene alcohols on Staphylococcus aureus and their mode of action. FEMS Microbiol. Lett. 2004, 237, 325-331.
16. Oluwatuyi, M.; Kaatz, G.W.; Gibbons, S. Antibacterial and resistance modifying activity of Rosmarinus officinalis. Phytochemistry 2004, 65, 3249-3254.
17. Stavri, M.; Piddock, L.J.; Gibbons, S. Bacterial efflux pump inhibitors from natural sources. J. Antimicrob. Chemother. 2007, 59, 1247-1260.
18. Jacobs, W.R., Jr. Mycobacterium Tuberculosis: A Once Genetically Intractable Organism. In Molecular Genetics of Mycobacteria; Hatfull, G.F., Jacobs, W.R., Jr., Eds.; ASM Press: Washington, DC, USA, 2000; pp. 1-36.
19. Coldham, N.G.; Webber, M.; Woodward, M.J.; Piddock, L.J. A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J. Antimicrob. Chemother. 2010, 65, 1655-1663.
20. Viveiros, M.; Leandro, C.; Amaral, L. Mycobacterial efflux pumps and chemotherapeutic implications. Int. J. Antimicrob. Agents 2003, 22, 274-278.
21. Li, X.Z.; Zhang, L.; Nikaido, H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 2004, 48, 2415-2423.
22. Kuroda, M.; Nagasaki, S.; Ito, R.; Ohta, T. Sesquiterpene farnesol as a competitive inhibitor of lipase activity of Staphylococcus aureus. FEMS Microbiol. Lett. 2007, 273, 28-34.
23. Ge, F.; Zeng, F.; Liu, S.; Guo, N.; Ye, H.; Song, Y.; Fan, J.; Wu, X.; Wang, X.; Deng, X.; Jin, Q.; Yu, L. In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. J. Med. Microbiol. 2010, 59, 567-572.
24. Guo, N.; Wu, X.; Yu, L.; Liu, J.; Meng, R.; Jin, J.; Lu, H.; Wang, X.; Yan, S.; Deng, X. In vitro and in vivo interactions between fluconazole and allicin against clinical isolates of fluconazole-resistant Candida albicans determined by alternative methods. FEMS Immunol. Med. Microbiol. 2010, 58, 193-201.
25. Spengler, G.; Martins, A.; Schelz, Z.; Rodrigues, L.; Aagaard, L.; Martins, M.; Costa, S.S.; Couto, I.; Viveiros, M.; Fanning, S.; Kristiansen, J.E.; Molnar, J.; Amaral, L. Characterization of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semi-automated ethidium bromide method. In Vivo 2009, 23, 81-87.
26. Couto, I.; Costa, S.S. Viveiros M, Martins M, Amaral L. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J. Antimicrob. Chemother. 2008, 62, 504-513.
27. Li, X.Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs 2004, 64, 159-204.
28. Poole, K. Efflux-mediated multiresistance in Gram negative bacteria. Clin. Microbiol. Infect. 2004, 10, 12-26.
29. Crowle, A.J.; Douvas, G.S.; May, M.H. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 1992, 38, 410-419.
30. Ramón-García, S.; Martín, C.; Aínsa, J.A.; De Rossi, E. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 2006, 57, 252-259.
31. Micol, V.; Mateo, C.R.; Shapiro, S.; Aranda, F.J.; Villalaín, J. Effects of (+)-totarol, a diterpenoid antibacterial agent, on phospholipid model membranes. Biochim. Biophys. Acta 2001, 1511, 281-290.
32. Ong, T.P.; Heidor, R.; de Conti, A.; Dagli, M.L.; Moreno, F.S. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 2006, 27, 1194-1203.
33. Koo, H.; Schobel, B.; Scott-Anne, K.; Watson, G.; Bowen, W.H.; Cury, J.A.; Rosalen, P.L.; Park, Y.K. Apigenin and tt-farnesol with fluoride effects on S. mutans biofilms and dental caries. J. Dent. Res. 2005, 84, 1016-1020.
34. Shirtliff, M.E.; Krom, B.P.; Meijering, R.A.; Peters, B.M.; Zhu, J.; Scheper, M.A.; Harris, M.L.; Jabra-Rizk, M.A. Farnesol-induced apoptosis in Candida albicans. Antimicrob. Agents Chemother. 2009, 53, 392-401.
35. Luft, U.C.; Bychkov, R.; Gollasch, M.; Gross, V.; Roullet, J.B.; McCarron, D.A.; Ried, C.; Hofmann, F.; Yagil, Y.; Yagil, C.; Haller, H.; Luft, F.C. Farnesol blocks the L-type Ca2+ channel by targeting the alpha 1C subunit. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 959-966.
36. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A; NCCLS: Wayne, PA, USA, 2003.
37. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin. Microbiol. Infect. 2000, 6, 503-508.
38. Odds, F.C. Synergy, antagonism, and what the checkerboard puts between them. J. Antimicrob. Chemother. 2003, 52, 1.